P2.04-10 Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients

Abstract

hepatitis. They also contributed to all-grade hypothyroidism, hyperthyroidism and pneumonitis. These toxicities have significant impact on patients' quality of life, ultimately affecting patients' compliance. A timely intervention with proper supportive care is necessary.

Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer

“…Peripheral densities of activated CD4 + T cells (CD69 + ) and NK cells (CD107a + ) were reduced post neoadjuvant therapy in patients who achieved pCR in resected tumors (78). Also, the authors found a decrease in the expression of PD-1 on peripheral CD4 + , CD8 + , and NK cells post neoadjuvant chemo-immunotherapy in patients who achieved pCR in resected tumors (78). Investigation of peripheral immunophenotyping in larger patient cohorts and across trials testing neoadjuvant immunotherapies are needed to validate these findings and determine whether various immune cell populations may serve as biomarkers of therapeutic efficacy.…”

“…Dynamic changes in peripheral immune cell populations following neoadjuvant immunotherapy and their association with tumor response to treatment are also being investigated in patients with resectable NSCLC for biomarker discovery. In these studies, blood samples were subjected to plasma-based cytokine arrays and analysis of PBMCs (peripheral blood mononuclear cells) by flow cytometry to identify the immunophenotypes of peripheral immune cells potentially associated with efficacy of ICIs (48,78). In the LCMC3 study (NCT02927301), blood samples were collected from patients pre-and posttreatment with neoadjuvant atezolizumab to investigate peripheral immunophenotyping and explore therapy-induced modulation of subsets of immune cell populations (48).…”

“…Interestingly, granulocyte (HLA-DR + CD33 + CD16 + ) and dendritic cell (HLA-DR + CD33 + CD11b + CD15 + ) subsets were expanded in patients who developed immune-related adverse events to neoadjuvant therapy (48). Preliminary results of correlative studies evaluating immune modulation in peripheral blood samples collected pre-and post-neoadjuvant chemotherapy plus nivolumab from patients with stage IIIA NSCLC from the NADIM trial (NCT03081689) have been reported (78). Peripheral densities of activated CD4 + T cells (CD69 + ) and NK cells (CD107a + ) were reduced post neoadjuvant therapy in patients who achieved pCR in resected tumors (78).…”

“…Preliminary results of correlative studies evaluating immune modulation in peripheral blood samples collected pre-and post-neoadjuvant chemotherapy plus nivolumab from patients with stage IIIA NSCLC from the NADIM trial (NCT03081689) have been reported (78). Peripheral densities of activated CD4 + T cells (CD69 + ) and NK cells (CD107a + ) were reduced post neoadjuvant therapy in patients who achieved pCR in resected tumors (78). Also, the authors found a decrease in the expression of PD-1 on peripheral CD4 + , CD8 + , and NK cells post neoadjuvant chemo-immunotherapy in patients who achieved pCR in resected tumors (78).…”

“…Absolute values of circulating blood cells collected during routine laboratory blood draws and ratios of complete blood cell counts have been investigated as potential markers of tumor response to ICIs (78)(79)(80)(81)(82). Reports examining the immune infiltrate in NSCLC indicate that neutrophils are among the most abundant cells found in NSCLCs (63,83).…”